R. Donald Harvey

7.4k total citations · 1 hit paper
167 papers, 4.8k citations indexed

About

R. Donald Harvey is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, R. Donald Harvey has authored 167 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 62 papers in Molecular Biology and 57 papers in Hematology. Recurrent topics in R. Donald Harvey's work include Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (29 papers) and Lung Cancer Treatments and Mutations (22 papers). R. Donald Harvey is often cited by papers focused on Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (29 papers) and Lung Cancer Treatments and Mutations (22 papers). R. Donald Harvey collaborates with scholars based in United States, United Kingdom and France. R. Donald Harvey's co-authors include Ching‐Hon Pui, Scott C. Howard, Randal K. Buddington, John McCormick, Sagar Lonial, Edward T. Morgan, Ashraf Badros, Taofeek K. Owonikoko, Richard L. Schilsky and Neeraj Gupta and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

R. Donald Harvey

153 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preventing and Managing Toxicities of High-Dose Methotrexate

2016 610 citations R. Donald Harvey et al. The Oncologist profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Donald Harvey United States	36	1.9k	1.8k	1.1k	760	625	167	4.8k
Helen K. Chew United States	34	1.0k 0.5×	1.4k 0.8×	580 0.5×	516 0.7×	394 0.6×	89	5.4k
Pere Gascón Spain	39	1.2k 0.6×	3.0k 1.7×	1.3k 1.2×	1.0k 1.4×	186 0.3×	163	5.8k
Kristine R. Crews United States	38	1.2k 0.6×	920 0.5×	622 0.6×	477 0.6×	1.5k 2.4×	100	4.9k
Louise B. Grochow United States	32	1.3k 0.7×	4.0k 2.3×	897 0.8×	1.5k 1.9×	556 0.9×	59	6.6k
James L. Wade United States	45	1.3k 0.7×	4.3k 2.4×	1.2k 1.1×	2.0k 2.6×	450 0.7×	153	7.6k
Wenjian Yang United States	38	1.9k 1.0×	913 0.5×	1.0k 1.0×	387 0.5×	2.5k 3.9×	114	5.5k
Jerome Seidenfeld United States	31	1.1k 0.6×	1.6k 0.9×	1.7k 1.6×	1.1k 1.4×	297 0.5×	71	5.3k
J.W.R. Nortier Netherlands	44	952 0.5×	3.5k 2.0×	1.5k 1.4×	1.2k 1.6×	355 0.6×	157	7.8k
François Goldwasser France	48	2.8k 1.4×	4.7k 2.6×	598 0.6×	2.1k 2.7×	412 0.7×	289	8.9k
Ali Shamseddine Lebanon	39	1.6k 0.9×	2.3k 1.3×	311 0.3×	1.1k 1.4×	205 0.3×	249	5.6k

Countries citing papers authored by R. Donald Harvey

Since Specialization

Citations

This map shows the geographic impact of R. Donald Harvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Donald Harvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Donald Harvey more than expected).

Fields of papers citing papers by R. Donald Harvey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Donald Harvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Donald Harvey. The network helps show where R. Donald Harvey may publish in the future.

Co-authorship network of co-authors of R. Donald Harvey

This figure shows the co-authorship network connecting the top 25 collaborators of R. Donald Harvey. A scholar is included among the top collaborators of R. Donald Harvey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Donald Harvey. R. Donald Harvey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shafer, Danielle, Dale Schaar, Dipankar Bandyopadhyay, et al.. (2025). A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancer Chemotherapy and Pharmacology. 95(1). 24–24. 5 indexed citations

Falchook, Gerald S., Amita Patnaik, Debra L. Richardson, et al.. (2024). A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clinical Therapeutics. 46(3). 228–238. 1 indexed citations

Switchenko, Jeffrey M., Madhusmita Behera, Mehmet Asım Bilen, et al.. (2023). Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The Oncologist. 28(12). 1055–1063.

Cash, Thomas F., Jan H. Beumer, Arhanti Sadanand, et al.. (2023). A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. Pediatric Blood & Cancer. 70(8). e30405–e30405. 10 indexed citations

Patil, Dattatraya, R. Donald Harvey, Janetta Bryksin, et al.. (2023). Race‐free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment. Cancer. 129(6). 920–924. 4 indexed citations

Alpert, Ash B., et al.. (2023). Debunking Sex and Disentangling Gender From Oncology. Journal of Clinical Oncology. 41(22). 3791–3795. 5 indexed citations

Liu, Yuan, Nisha S. Joseph, Craig C. Hofmeister, et al.. (2023). Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO Oncology Practice. 19(9). 793–798. 7 indexed citations

Harvey, R. Donald, Suanna S. Bruinooge, Li Chen, et al.. (2021). Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations. Clinical Cancer Research. 27(9). 2430–2434. 29 indexed citations

Griggs, Jennifer J., Kari Bohlke, Edward P. Balaban, et al.. (2021). Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 39(18). 2037–2048. 75 indexed citations

10.

Kaufman, Jonathan L., Roberto Mina, Jatin J. Shah, et al.. (2020). Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(12). 797–803. 5 indexed citations

11.

Kluetz, Paul G., Patricia Keegan, George D. Demetri, et al.. (2020). FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. Clinical Cancer Research. 27(4). 916–921. 8 indexed citations

12.

Vishwanathan, Karthick, Mireille Cantarini, Karen So, et al.. (2019). Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer. Clinical and Translational Science. 13(1). 41–46. 3 indexed citations

13.

Harvey, R. Donald, Boris Spektor, Kimberly Curseen, et al.. (2018). Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial. JMIR Research Protocols. 8(4). e12125–e12125. 1 indexed citations

14.

Shah, Jatin J., Andrzej Jakubowiak, Owen A. O’Connor, et al.. (2015). Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 22(1). 34–43. 162 indexed citations

15.

Sarantopoulos, John, Geoffrey I. Shapiro, Roger B. Cohen, et al.. (2015). Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 847–857. 139 indexed citations

16.

Wilson, Nicole, et al.. (2012). Bortezomib Administration With Severe Hyperbilirubinemia Caused by Hepatic Plasma Cell Infiltration: A Case Report. Clinical Lymphoma Myeloma & Leukemia. 13(2). 159–161. 1 indexed citations

17.

Lonial, Sagar, Adam D. Cohen, Jeffrey A. Zonder, et al.. (2011). The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood. 118(21). 2935–2935. 4 indexed citations

18.

Innerfield, Irving, et al.. (1964). Inhibition of the generalized Shwartzman reaction in the pregnant golden Hamster by oral streptokinase. Life Sciences. 3(7). 673–678.

19.

Hardinge, Mervyn G., et al.. (1963). Action of Plant Extracts on Transplanted Mouse Tumors. Cancer Research. 23. 981–1010. 4 indexed citations

20.

Hardinge, Mervyn G., et al.. (1961). ACTION OF PLANT EXTRACTS ON TRANSPLANTED MOUSE TUMORS. SCREENING DATA II.. Cancer Research. 21(1 Pt 1). 1–1010. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact